LT2640358T - L-dopa, dopa dekarboksilazės inhibitoriaus, katechol-o-metilo transferazės inhibitoriaus ir jų kompozicijų nepertraukiamas vartojimas - Google Patents

L-dopa, dopa dekarboksilazės inhibitoriaus, katechol-o-metilo transferazės inhibitoriaus ir jų kompozicijų nepertraukiamas vartojimas

Info

Publication number: LT2640358T
Authority: LT; Lithuania
Prior art keywords: dopa; inhibitors; catechol; compositions; same
Prior art date: 2010-11-15

Application number

LTEP11808359.1T

Other languages

English (en)

Inventor

Oron Yacoby-Zeevi

Mara Nemas

Original Assignee

Neuroderm Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-15

Filing date

2011-11-15

Publication date

2018-03-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45478410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2640358(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-11-15 Application filed by Neuroderm Ltd filed Critical Neuroderm Ltd

2018-03-26 Publication of LT2640358T publication Critical patent/LT2640358T/lt

Links

WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title 1
239000003543 catechol methyltransferase inhibitor Substances 0.000 title 1
239000000534 dopa decarboxylase inhibitor Substances 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Psychology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)

LTEP11808359.1T 2010-11-15 2011-11-15 L-dopa, dopa dekarboksilazės inhibitoriaus, katechol-o-metilo transferazės inhibitoriaus ir jų kompozicijų nepertraukiamas vartojimas LT2640358T (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US41363710P	2010-11-15	2010-11-15
US201161524064P	2011-08-16	2011-08-16
PCT/IL2011/000881 WO2012066538A1 (en)	2010-11-15	2011-11-15	Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same

Publications (1)

Publication Number	Publication Date
LT2640358T true LT2640358T (lt)	2018-03-26

Family

ID=45478410

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP11808359.1T LT2640358T (lt)	2010-11-15	2011-11-15	L-dopa, dopa dekarboksilazės inhibitoriaus, katechol-o-metilo transferazės inhibitoriaus ir jų kompozicijų nepertraukiamas vartojimas

Country Status (27)

Country	Link
US (7)	US9421267B2 (lt)
EP (3)	EP2640358B1 (lt)
JP (3)	JP5902705B2 (lt)
KR (1)	KR101859242B1 (lt)
CN (2)	CN103442693A (lt)
AU (1)	AU2011330757B2 (lt)
BR (1)	BR112013011685B1 (lt)
CA (1)	CA2817888C (lt)
CL (1)	CL2013001368A1 (lt)
CY (1)	CY1120005T1 (lt)
DK (2)	DK3326615T3 (lt)
ES (2)	ES2660772T3 (lt)
HR (2)	HRP20180514T1 (lt)
HU (2)	HUE047841T2 (lt)
IL (1)	IL263954A (lt)
LT (1)	LT2640358T (lt)
MX (1)	MX348225B (lt)
NZ (1)	NZ610911A (lt)
PL (2)	PL2640358T3 (lt)
PT (2)	PT2640358T (lt)
RS (1)	RS57047B1 (lt)
RU (2)	RU2607497C2 (lt)
SG (2)	SG190258A1 (lt)
SI (1)	SI2640358T1 (lt)
SM (1)	SMT201800145T1 (lt)
WO (1)	WO2012066538A1 (lt)
ZA (1)	ZA201303509B (lt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010134074A1 (en)	2009-05-19	2010-11-25	Neuroderm Ltd	Compositions for continuous administration of dopa decarboxylase inhibitors
EP2640370B1 (en)	2010-11-15	2018-03-14	Neuroderm Ltd	Compositions for transdermal delivery of active agents
EP2640358B1 (en)	2010-11-15	2018-01-03	Neuroderm Ltd	Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
PL2854764T3 (pl)	2012-06-05	2019-07-31	Neuroderm Ltd	Kompozycje zawierające apomorfinę i kwasy organiczne oraz ich zastosowania
PT2968218T (pt) *	2013-03-13	2021-09-24	Neuroderm Ltd	Combinação para tratamento da doença de parkinson
WO2015115512A1 (ja) *	2014-01-29	2015-08-06	独立行政法人産業技術総合研究所	シクロデキストリンの利用による抗がん活性が増強されたアシュワガンダ葉の水抽出物の調製方法、及びアシュワガンダ葉を含む医薬組成物
US10258585B2 (en)	2014-03-13	2019-04-16	Neuroderm, Ltd.	DOPA decarboxylase inhibitor compositions
ES2967693T3 (es) *	2014-03-13	2024-05-03	Neuroderm Ltd	Composiciones del inhibidor de la dopa descarboxilasa
PT3782617T (pt)	2014-09-04	2024-02-29	Lobsor Pharmaceuticals Ab	Composições farmacêuticas de gel compreendendo levodopa, carbidopa e entacapona
RU2743347C2 (ru)	2014-10-21	2021-02-17	Эббви Инк.	Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
MA41377A (fr) *	2015-01-20	2017-11-28	Abbvie Inc	Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
DK3277660T3 (da)	2015-03-30	2020-01-27	Berlirem Gmbh	Vandopløselige L-DOPA-estere
EP3075723B1 (en)	2015-03-30	2017-05-24	Berlirem GmbH	Highly soluble l-dopa glycerol esters
AU2016258179B2 (en)	2015-05-06	2021-07-01	Synagile Corporation	Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
WO2017039525A1 (en) *	2015-09-04	2017-03-09	Lobsor Pharmaceuticals Aktiebolag	Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
EP3445346A1 (en) *	2016-04-20	2019-02-27	AbbVie Inc.	Carbidopa and l-dopa prodrugs and methods of use
EP3275433A1 (en) *	2016-07-29	2018-01-31	Som Innovation Biotech S.L.	Sustained release composition comprising micronized tolcapone
CN106619490A (zh) *	2017-01-19	2017-05-10	云南白药集团无锡药业有限公司	一种左旋多巴透皮贴剂及其制备方法
HUE054268T2 (hu) *	2017-06-05	2021-08-30	Dizlin Pharmaceuticals Ab	Levodopa infúziós oldat
RU2765171C2 (ru)	2017-07-07	2022-01-26	Нейродерм Лтд	Устройство для подкожной доставки текучего лекарственного средства
US11547689B2 (en)	2018-03-23	2023-01-10	Intrance International Ab	Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
CN113015531A (zh)	2018-11-15	2021-06-22	艾伯维公司	用于皮下施用的药物调配物
CN111701024B (zh) *	2020-05-26	2022-05-24	上海京新生物医药有限公司	一种左旋多巴制剂及其制备方法及其应用
CN111643493B (zh) *	2020-05-26	2023-01-10	上海京新生物医药有限公司	一种高浓度左旋多巴制剂及其制备方法及其应用
US20230181508A1 (en) *	2020-08-31	2023-06-15	Purdue Pharma L.P.	Compositions and methods for levodopa delivery
US11213502B1 (en) *	2020-11-17	2022-01-04	Neuroderm, Ltd.	Method for treatment of parkinson's disease
US11844754B2 (en)	2020-11-17	2023-12-19	Neuroderm, Ltd.	Methods for treatment of Parkinson's disease
US11331293B1 (en)	2020-11-17	2022-05-17	Neuroderm, Ltd.	Method for treatment of Parkinson's disease
US20240207410A1 (en) *	2021-03-10	2024-06-27	Neuroderm, Ltd.	Stabilized liquid compositions comprising a levodopa-tyrosine conjugate and uses thereof
EP4460289A4 (en) *	2022-01-03	2025-09-03	Neuroderm Ltd	METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE
EP4223288B1 (en)	2022-02-07	2024-03-06	Berlirem GmbH	Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
US12161612B2 (en)	2023-04-14	2024-12-10	Neuroderm, Ltd.	Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3808317A (en) *	1969-10-29	1974-04-30	Alcon Labor Inc	Stabilized aqueous borate complexes of biologically active catechol amines
US3936495A (en)	1973-11-27	1976-02-03	Merck & Co., Inc.	Purification process
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4241082A (en)	1977-09-02	1980-12-23	Sankyo Company Limited	Agents for promoting reproductive ability of domestic animals
JPS5450700A (en)	1977-09-28	1979-04-20	Sankyo Co	Glazing agent of animal leather
JPS6021570B2 (ja) *	1978-07-04	1985-05-28	三共株式会社	ド−パ類の高濃度製剤の製法
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
US4642316A (en)	1985-05-20	1987-02-10	Warner-Lambert Company	Parenteral phenytoin preparations
ES2042520T3 (es)	1986-06-10	1993-12-16	Chiesi Farma Spa	Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
US4684666A (en)	1986-08-19	1987-08-04	Haas Pharmaceuticals, Inc.	Stabilized liquid analgesic compositions
US4963568A (en) *	1989-05-31	1990-10-16	Abbott Laboratories	Dopamine agonists
US5350769A (en)	1990-10-30	1994-09-27	Ss Pharmaceutical Co., Ltd.	Antiinflammatory gel preparation
US5877176A (en)	1991-12-26	1999-03-02	Cornell Research Foundation, Inc.	Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
GB9523833D0 (en) *	1995-11-22	1996-01-24	Boots Co Plc	Medical treatment
IL119417A (en) *	1996-10-13	2003-02-12	Moshe Kushnir	Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
US5861423A (en)	1997-02-21	1999-01-19	Caldwell; William Scott	Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
AU1917899A (en)	1998-03-20	1999-10-18	Warner-Lambert Company	Crystalline sodium phenytoin monohydrate
US7201923B1 (en)	1998-03-23	2007-04-10	General Mills, Inc.	Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
ATE271864T1 (de)	1998-05-15	2004-08-15	Warner Lambert Co	Aminosäure-stabilisierte gabapentin und pregabalin zubereitungen und verfahren zu ihrer herstellung
US6274168B1 (en)	1999-02-23	2001-08-14	Mylan Pharmaceuticals Inc.	Phenytoin sodium pharmaceutical compositions
US6716452B1 (en)	2000-08-22	2004-04-06	New River Pharmaceuticals Inc.	Active agent delivery systems and methods for protecting and administering active agents
WO2000054773A1 (en)	1999-03-12	2000-09-21	Nitromed, Inc.	Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
FI109453B (fi) *	1999-06-30	2002-08-15	Orion Yhtymae Oyj	Farmaseuttinen koostumus
US7479498B2 (en)	1999-08-23	2009-01-20	Phoenix Biosciences, Inc.	Treatments for viral infections
US6348965B1 (en)	1999-09-24	2002-02-19	Henry Palladino	Solid state fluorescence and absorption spectroscopy
SE0001151D0 (sv)	2000-03-31	2000-03-31	Amarin Dev Ab	Method for producing a controlled-release composition
US20020028799A1 (en)	2000-07-06	2002-03-07	Naylor Alasdair Mark	Treatment of male sexual dysfunction
GB0017387D0 (en)	2000-07-14	2000-08-30	Pfizer Ltd	Novel enzyme
US20020099013A1 (en)	2000-11-14	2002-07-25	Thomas Piccariello	Active agent delivery systems and methods for protecting and administering active agents
US20030119714A1 (en)	2000-12-15	2003-06-26	Naylor Alasdair Mark	Treatment of male sexual dysfunction
EP1347750A1 (en) *	2000-12-15	2003-10-01	Pfizer Limited	Treatment of male sexual dysfunction
EP1450901A4 (en)	2001-12-10	2005-05-25	Bristol Myers Squibb Co	(1-PHENYL-2-HETEROARYL) ETHYL-GUANIDINE COMPOUNDS AS AN INHIBITORS OF MITOCHONDRIAL F1F0 ATP HYDROLASE
MXPA04009906A (es)	2002-04-11	2004-12-13	Ranbaxy Lab Ltd	Composiciones farmaceuticas de liberacion controlada de carbipoda y levopoda.
US7985422B2 (en)	2002-08-05	2011-07-26	Torrent Pharmaceuticals Limited	Dosage form
DE10247233A1 (de) *	2002-10-10	2004-06-17	Morphochem AG Aktiengesellschaft für kombinatorische Chemie	Neue Verbindungen, die Topoisomerase IV inhibieren
WO2004035569A2 (de) *	2002-10-10	2004-04-29	Morphochem Aktiengesellschaft für kombinatorische Chemie	Neue verbindungen mit antibakterieller aktivität
RU2426590C2 (ru)	2003-07-18	2011-08-20	Бакстер Интернэшнл Инк.	Способы изготовления, применение и композиции небольших сферических частиц, приготовленных регулируемым фазовым разделением
US8173840B2 (en)	2003-07-29	2012-05-08	Signature R&D Holdings, Llc	Compounds with high therapeutic index
US7589233B2 (en)	2003-07-29	2009-09-15	Signature R&D Holdings, Llc	L-Threonine derivatives of high therapeutic index
GB0319935D0 (en)	2003-08-26	2003-09-24	Cipla Ltd	Polymorphs
US20050053669A1 (en) *	2003-09-05	2005-03-10	Boehringer Ingelheim International Gmbh	Administration form for the oral application of poorly soluble acidic and amphorteric drugs
EP1677759A1 (en)	2003-10-31	2006-07-12	Alza Corporation	Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
WO2005099678A1 (en) *	2004-04-06	2005-10-27	Transform Pharmaceuticals, Inc.	Pharmaceutical compositions and method of using levodopa and carbidopa
SE0401842D0 (sv)	2004-07-12	2004-07-12	Dizlin Medical Design Ab	Infusion and injection solution of levodopa
WO2006029411A2 (en)	2004-09-09	2006-03-16	Yeda Research And Development Co. Ltd.	Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
WO2006037061A2 (en)	2004-09-28	2006-04-06	Farouk Karoum	Compositions and methods of using d-dopa to treat parkinson's disease
CA2582346A1 (en) *	2004-10-01	2006-04-13	The Research Foundation Of State University Of New York	Morphine and morphine precursors
DE102006021872B4 (de) *	2006-05-11	2008-04-17	Sanofi-Aventis	4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
RU2484815C2 (ru) *	2006-05-31	2013-06-20	Зольвай Фармасьютиклз Гмбх	Продолжительное 24-часовое введение в кишечник леводопа/карбидопа
CA2606658A1 (en)	2006-10-13	2008-04-13	Mike Tyers	Compositions and methods for treating neurological disorders or damage
CA2682888A1 (en)	2007-04-06	2008-10-16	Transform Pharmaceuticals, Inc.	Systems and methods for delivering a fluid drug
CN101669925B (zh)	2008-09-10	2011-08-10	天津药物研究院	干粉吸入剂、其制备方法和用途
US20130253056A1 (en)	2009-05-19	2013-09-26	Neuroderm, Ltd.	Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
WO2010134074A1 (en)	2009-05-19	2010-11-25	Neuroderm Ltd	Compositions for continuous administration of dopa decarboxylase inhibitors
CN101987081B (zh)	2010-07-16	2012-08-08	钟术光	一种控释制剂
KR101187064B1 (ko)	2010-07-18	2012-09-28	주식회사 바이오폴리메드	양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체
US10150792B2 (en)	2010-11-08	2018-12-11	Synthonics, Inc.	Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients
EP2640358B1 (en)	2010-11-15	2018-01-03	Neuroderm Ltd	Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
EP2640370B1 (en)	2010-11-15	2018-03-14	Neuroderm Ltd	Compositions for transdermal delivery of active agents
BR112013014304A2 (pt)	2010-12-10	2016-07-19	Synagile Corp	composições de pró-fármaco levodopa infundíveis subcutaneamente e método de infusão
US20130116215A1 (en)	2011-10-28	2013-05-09	Mireia Coma	Combination therapies for treating neurological disorders
PT2968218T (pt)	2013-03-13	2021-09-24	Neuroderm Ltd	Combinação para tratamento da doença de parkinson
ES2967693T3 (es)	2014-03-13	2024-05-03	Neuroderm Ltd	Composiciones del inhibidor de la dopa descarboxilasa

2011
- 2011-11-15 EP EP11808359.1A patent/EP2640358B1/en active Active
- 2011-11-15 PL PL11808359T patent/PL2640358T3/pl unknown
- 2011-11-15 PT PT118083591T patent/PT2640358T/pt unknown
- 2011-11-15 RS RS20180386A patent/RS57047B1/sr unknown
- 2011-11-15 CA CA2817888A patent/CA2817888C/en active Active
- 2011-11-15 SG SG2013036678A patent/SG190258A1/en unknown
- 2011-11-15 SG SG10201509316SA patent/SG10201509316SA/en unknown
- 2011-11-15 JP JP2013538326A patent/JP5902705B2/ja active Active
- 2011-11-15 SI SI201131440T patent/SI2640358T1/en unknown
- 2011-11-15 RU RU2013123457A patent/RU2607497C2/ru active
- 2011-11-15 PL PL17207731T patent/PL3326615T3/pl unknown
- 2011-11-15 SM SM20180145T patent/SMT201800145T1/it unknown
- 2011-11-15 HR HRP20180514TT patent/HRP20180514T1/hr unknown
- 2011-11-15 PT PT172077315T patent/PT3326615T/pt unknown
- 2011-11-15 WO PCT/IL2011/000881 patent/WO2012066538A1/en not_active Ceased
- 2011-11-15 LT LTEP11808359.1T patent/LT2640358T/lt unknown
- 2011-11-15 DK DK17207731.5T patent/DK3326615T3/da active
- 2011-11-15 AU AU2011330757A patent/AU2011330757B2/en active Active
- 2011-11-15 ES ES11808359.1T patent/ES2660772T3/es active Active
- 2011-11-15 MX MX2013005493A patent/MX348225B/es active IP Right Grant
- 2011-11-15 DK DK11808359.1T patent/DK2640358T3/en active
- 2011-11-15 ES ES17207731T patent/ES2776734T3/es active Active
- 2011-11-15 NZ NZ610911A patent/NZ610911A/en not_active IP Right Cessation
- 2011-11-15 BR BR112013011685-4A patent/BR112013011685B1/pt active IP Right Grant
- 2011-11-15 RU RU2016147575A patent/RU2740080C2/ru active
- 2011-11-15 CN CN2011800648945A patent/CN103442693A/zh active Pending
- 2011-11-15 CN CN201910369050.XA patent/CN110123743A/zh active Pending
- 2011-11-15 US US13/885,518 patent/US9421267B2/en active Active
- 2011-11-15 HU HUE17207731A patent/HUE047841T2/hu unknown
- 2011-11-15 HU HUE11808359A patent/HUE037005T2/hu unknown
- 2011-11-15 EP EP20150020.4A patent/EP3692982A1/en not_active Withdrawn
- 2011-11-15 EP EP17207731.5A patent/EP3326615B1/en active Active
- 2011-11-15 KR KR1020137015306A patent/KR101859242B1/ko active Active
2013
- 2013-05-15 CL CL2013001368A patent/CL2013001368A1/es unknown
- 2013-05-30 ZA ZA2013/03509A patent/ZA201303509B/en unknown
2014
- 2014-04-02 US US14/243,625 patent/US9040577B2/en active Active
- 2014-04-02 US US14/243,638 patent/US9040578B2/en active Active
2016
- 2016-03-10 JP JP2016047187A patent/JP6231145B2/ja active Active
- 2016-07-13 US US15/209,423 patent/US20170157077A1/en not_active Abandoned
2017
- 2017-10-18 JP JP2017201780A patent/JP6387171B2/ja active Active
2018
- 2018-03-06 CY CY20181100276T patent/CY1120005T1/el unknown
- 2018-12-24 IL IL263954A patent/IL263954A/en unknown
2020
- 2020-01-22 US US16/749,435 patent/US20200397730A1/en not_active Abandoned
- 2020-03-04 HR HRP20200366TT patent/HRP20200366T1/hr unknown
2022
- 2022-03-16 US US17/696,243 patent/US20230047523A1/en not_active Abandoned
2024
- 2024-04-12 US US18/633,746 patent/US20250114315A1/en active Pending

Also Published As

Publication number	Publication date
CA2817888A1 (en)	2012-05-24
AU2011330757A1 (en)	2013-06-06
PL2640358T3 (pl)	2018-06-29
JP2016106146A (ja)	2016-06-16
JP2013545745A (ja)	2013-12-26
SG10201509316SA (en)	2015-12-30
HUE047841T2 (hu)	2020-05-28
US9040578B2 (en)	2015-05-26
BR112013011685B1 (pt)	2022-03-03
EP2640358A1 (en)	2013-09-25
CY1120005T1 (el)	2018-12-12
US20140051755A1 (en)	2014-02-20
ZA201303509B (en)	2014-12-23
CN103442693A (zh)	2013-12-11
EP3326615A1 (en)	2018-05-30
ES2776734T3 (es)	2020-07-31
EP3326615B1 (en)	2020-01-08
DK3326615T3 (da)	2020-03-09
PL3326615T3 (pl)	2020-07-27
RU2016147575A (ru)	2018-10-23
US20140249228A1 (en)	2014-09-04
RS57047B1 (sr)	2018-05-31
CL2013001368A1 (es)	2014-09-05
JP5902705B2 (ja)	2016-04-13
PT2640358T (pt)	2018-02-23
JP2018030877A (ja)	2018-03-01
HRP20180514T1 (hr)	2018-05-04
MX348225B (es)	2017-05-31
MX2013005493A (es)	2013-09-06
SI2640358T1 (en)	2018-05-31
US9040577B2 (en)	2015-05-26
US20250114315A1 (en)	2025-04-10
BR112013011685A2 (pt)	2016-08-09
WO2012066538A1 (en)	2012-05-24
US20200397730A1 (en)	2020-12-24
SG190258A1 (en)	2013-06-28
DK2640358T3 (en)	2018-04-16
US20230047523A1 (en)	2023-02-16
EP3692982A1 (en)	2020-08-12
NZ610911A (en)	2015-02-27
PT3326615T (pt)	2020-03-23
JP6387171B2 (ja)	2018-09-05
SMT201800145T1 (it)	2018-05-02
US20140249229A1 (en)	2014-09-04
US9421267B2 (en)	2016-08-23
EP2640358B1 (en)	2018-01-03
RU2013123457A (ru)	2014-12-27
AU2011330757B2 (en)	2016-05-26
RU2740080C2 (ru)	2021-01-11
RU2016147575A3 (lt)	2020-03-04
ES2660772T3 (es)	2018-03-26
US20170157077A1 (en)	2017-06-08
KR101859242B1 (ko)	2018-05-17
CA2817888C (en)	2018-12-11
HUE037005T2 (hu)	2018-08-28
KR20130140075A (ko)	2013-12-23
HRP20200366T1 (hr)	2020-07-10
CN110123743A (zh)	2019-08-16
IL263954A (en)	2019-01-31
RU2607497C2 (ru)	2017-01-10
JP6231145B2 (ja)	2017-11-15

Publication	Publication Date	Title
IL263954A (en)	2019-01-31	Continuous administration of l-dopa, dopa decarboxylase inhibitors, o-methyltransferase inhibitors, and pharmaceutical preparations that include them
IL216383A0 (en)	2012-01-31	Compositions for continuous administration of dopa decarboxylase inhibitors
ZA201206223B (en)	2013-04-24	Certain kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions, and methods of use thereof
ZA201401117B (en)	2017-09-27	Kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions,and methods of use thereof
IL253911A0 (en)	2017-10-31	Inhibitors of kynurenine-3-monooxygenase, pharmaceutical compositions, and methods of their use
IL210843A0 (en)	2011-04-28	Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
IL220863A (en)	2017-11-30	Oxazole derivatives of kinase inhibitors, medicinal preparations containing them and their uses
IL230705A0 (en)	2014-03-31	Certain inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
IL223865B (en)	2018-04-30	Calcium salts of dihydroortate dehydrogenase inhibitors, preparations containing them and their uses
EP2534145A4 (en)	2013-09-11	THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING THE INHIBITION OF ALLOSTERIC KINASE
EP3188725A4 (en)	2018-04-25	Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof
PL2642993T3 (pl)	2016-09-30	Kompozycje rotygotyny lub farmaceutycznie dopuszczalnych soli rotygotyny
TN2013000239A1 (en)	2014-11-10	New form of administration of enkephalinase inhibitor
EP2424533A4 (en)	2012-10-17	SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE AS-SECRETASE INHIBITORS
IL226239A0 (en)	2013-07-31	Continuous administration of l-dopa, dopa decarboxylase inhibitors, o-methyl inhibitors
EP2588081A4 (en)	2014-12-10	ORAL FORMULATION OF CHINESE INHIBITORS
HK1177101A (en)	2013-08-16	Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof